John Sourbeer
Stock Analyst at UBS
(0.68)
# 3,753
Out of 4,735 analysts
34
Total ratings
35.29%
Success rate
-25.32%
Average return
Main Sectors:
Stocks Rated by John Sourbeer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Upgrades: Buy | $350 → $390 | $336.34 | +15.95% | 3 | Dec 12, 2024 | |
| PACB Pacific Biosciences of California | Downgrades: Neutral | $2 | $1.64 | +21.95% | 3 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Neutral | $133 → $145 | $136.67 | +6.09% | 3 | Nov 5, 2024 | |
| QDEL QuidelOrtho | Upgrades: Neutral | $42 → $50 | $41.74 | +19.79% | 2 | Sep 19, 2024 | |
| OMIC Singular Genomics Systems | Maintains: Neutral | $12 → $15 | $19.70 | -23.86% | 2 | Mar 20, 2024 | |
| CYRX Cryoport | Maintains: Neutral | $15 → $17 | $7.50 | +126.67% | 4 | Mar 15, 2024 | |
| MEDP Medpace Holdings | Maintains: Buy | $452 → $480 | $337.35 | +42.29% | 4 | Mar 8, 2024 | |
| AKYA Akoya Biosciences | Maintains: Buy | $7 → $7.5 | $2.82 | +165.96% | 2 | Mar 5, 2024 | |
| BRKR Bruker | Maintains: Buy | $94 → $102 | $56.88 | +79.32% | 3 | Mar 1, 2024 | |
| QGEN Qiagen | Maintains: Neutral | $49 → $43 | $46.00 | -5.96% | 3 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $50 | $15.08 | +231.56% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $270 | $198.11 | +36.29% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $142 → $128 | $113.48 | +12.80% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $22 | $22.85 | -3.72% | 1 | Aug 10, 2021 |
West Pharmaceutical Services
Dec 12, 2024
Upgrades: Buy
Price Target: $350 → $390
Current: $336.34
Upside: +15.95%
Pacific Biosciences of California
Nov 11, 2024
Downgrades: Neutral
Price Target: $2
Current: $1.64
Upside: +21.95%
Illumina
Nov 5, 2024
Maintains: Neutral
Price Target: $133 → $145
Current: $136.67
Upside: +6.09%
QuidelOrtho
Sep 19, 2024
Upgrades: Neutral
Price Target: $42 → $50
Current: $41.74
Upside: +19.79%
Singular Genomics Systems
Mar 20, 2024
Maintains: Neutral
Price Target: $12 → $15
Current: $19.70
Upside: -23.86%
Cryoport
Mar 15, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $7.50
Upside: +126.67%
Medpace Holdings
Mar 8, 2024
Maintains: Buy
Price Target: $452 → $480
Current: $337.35
Upside: +42.29%
Akoya Biosciences
Mar 5, 2024
Maintains: Buy
Price Target: $7 → $7.5
Current: $2.82
Upside: +165.96%
Bruker
Mar 1, 2024
Maintains: Buy
Price Target: $94 → $102
Current: $56.88
Upside: +79.32%
Qiagen
Nov 2, 2023
Maintains: Neutral
Price Target: $49 → $43
Current: $46.00
Upside: -5.96%
Feb 2, 2023
Initiates: Neutral
Price Target: $50
Current: $15.08
Upside: +231.56%
Sep 7, 2022
Initiates: Buy
Price Target: $270
Current: $198.11
Upside: +36.29%
Jul 27, 2022
Maintains: Buy
Price Target: $142 → $128
Current: $113.48
Upside: +12.80%
Aug 10, 2021
Initiates: Neutral
Price Target: $22
Current: $22.85
Upside: -3.72%